William Blair reiterated their outperform rating on shares of Biogen Inc (NASDAQ:BIIB) in a research note released on Wednesday, Analyst Ratings Network.com reports.

In related news, CMO Alfred Sandrock sold 441 shares of the firm’s stock in a transaction on Friday, December 4th. The shares were sold at an average price of $277.00, for a total value of $122,157.00. Following the transaction, the chief marketing officer now directly owns 7,740 shares in the company, valued at approximately $2,143,980. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

A number of hedge funds and institutional investors have recently bought and sold shares of BIIB. Detwiler Fenton Investment Management purchased a new position in Biogen during the fourth quarter worth about $266,000. Ferguson Wellman Capital Management Inc. purchased a new position in Biogen during the fourth quarter worth about $269,000. Atria Investments raised its position in Biogen by 27.3% in the fourth quarter. Atria Investments now owns 900 shares of the biotechnology company’s stock worth $253,000 after buying an additional 193 shares during the last quarter. JNBA Financial Advisors raised its position in Biogen by 26.5% in the fourth quarter. JNBA Financial Advisors now owns 931 shares of the biotechnology company’s stock worth $285,000 after buying an additional 195 shares during the last quarter. Finally, Harvest Management bought a new stake in Biogen during the third quarter valued at about $292,000.

Biogen (NASDAQ:BIIB) opened at 273.26 on Wednesday. Biogen has a one year low of $254.00 and a one year high of $480.18. The firm has a market capitalization of $60.91 billion and a P/E ratio of 17.86. The firm has a 50-day moving average price of $286.11 and a 200 day moving average price of $300.08.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, January 27th. The biotechnology company reported $4.50 EPS for the quarter, topping the consensus estimate of $4.08 by $0.42. The firm earned $2.84 billion during the quarter, compared to the consensus estimate of $2.70 billion. Biogen’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the company posted $4.09 EPS. Equities research analysts anticipate that Biogen will post $16.60 earnings per share for the current year.

Several other research analysts have also recently issued reports on the stock. Cowen and Company reiterated a buy rating on shares of Biogen in a report on Wednesday. Piper Jaffray reiterated a neutral rating and issued a $293.00 price objective on shares of Biogen in a report on Wednesday. Zacks Investment Research upgraded shares of Biogen from a hold rating to a buy rating and set a $301.00 price objective for the company in a report on Monday. Barclays reiterated a buy rating and issued a $420.00 price objective on shares of Biogen in a report on Friday, January 22nd. Finally, Wells Fargo reiterated an outperform rating on shares of Biogen in a report on Friday, January 22nd. Nine equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. Biogen presently has an average rating of Buy and an average target price of $375.29.

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (NASDAQ:BIIB) and hemophilia A and B. The Company’s marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

12 Month Chart for NASDAQ:BIIB

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.